Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1987 1
1990 1
1993 2
1995 1
1998 3
2000 1
2001 2
2002 2
2003 2
2004 4
2005 5
2006 14
2007 17
2008 25
2009 40
2010 39
2011 56
2012 74
2013 84
2014 86
2015 85
2016 94
2017 86
2018 96
2019 141
2020 162
2021 162
2022 177
2023 148
2024 78

Text availability

Article attribute

Article type

Publication date

Search Results

1,371 results

Results by year

Filters applied: . Clear all
Page 1
Neurological update: MOG antibody disease.
Wynford-Thomas R, Jacob A, Tomassini V. Wynford-Thomas R, et al. J Neurol. 2019 May;266(5):1280-1286. doi: 10.1007/s00415-018-9122-2. Epub 2018 Dec 19. J Neurol. 2019. PMID: 30569382 Free PMC article. Review.
Residual disability develops in 50-80% of patients, with transverse myelitis at onset being the most significant predictor of long-term outcome. Recent advances in MOG antibody testing offer improved sensitivity and specificity. ...MRI characteristics can help in different …
Residual disability develops in 50-80% of patients, with transverse myelitis at onset being the most significant predictor of long-te …
Treatment of Neuromyelitis Optica Spectrum Disorders.
Chan KH, Lee CY. Chan KH, et al. Int J Mol Sci. 2021 Aug 11;22(16):8638. doi: 10.3390/ijms22168638. Int J Mol Sci. 2021. PMID: 34445343 Free PMC article. Review.
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system (CNS) inflammatory disorder that can lead to serious disability and mortality. ...Future directions include the identification of clinically useful biomarkers for the predictio …
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system (CNS) inflammatory disorder that can le …
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Yamamura T, et al. N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747. N Engl J Med. 2019. PMID: 31774956 Clinical Trial.
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. ...Key secondary end points were the chang …
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is assoc …
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T, Blair HA. Nie T, et al. CNS Drugs. 2022 Oct;36(10):1133-1141. doi: 10.1007/s40263-022-00949-7. Epub 2022 Sep 7. CNS Drugs. 2022. PMID: 36070074 Free PMC article. Review.
Inebilizumab (Uplizna()) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody seropositive. ...Thus, inebilizumab is an effective treatment option for adults with AQ …
Inebilizumab (Uplizna()) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectrum disor …
The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D. Karussis D. J Autoimmun. 2014 Feb-Mar;48-49:134-42. doi: 10.1016/j.jaut.2014.01.022. Epub 2014 Feb 10. J Autoimmun. 2014. PMID: 24524923 Review.
These include the initial events of demyelination defined as clinically or radiologically isolated syndromes (CIS and RIS respectively), acute disseminated encephalomyelitis (ADEM) and its variants (acute hemorrhagic leukoencephalitis-AHL, Marburg variant, and Balo's concentric s …
These include the initial events of demyelination defined as clinically or radiologically isolated syndromes (CIS and RIS respectively), acu …
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial.
Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E. Rensel M, et al. Mult Scler. 2022 May;28(6):925-932. doi: 10.1177/13524585211047223. Epub 2021 Oct 1. Mult Scler. 2022. PMID: 34595983 Free PMC article. Clinical Trial.
BACKGROUND: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)-immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmentum study. ...CONC …
BACKGROUND: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive …
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Büdingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Kleiter I, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724181 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo in 2 independent, double-blind studies in patients with neuromyelitis optica spectrum disorder (NMOSD). We assessed the long-t …
BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo …
Cerebral enhancement in MOG antibody-associated disease.
Elsbernd P, Cacciaguerra L, Krecke KN, Chen JJ, Gritsch D, Lopez-Chiriboga AS, Sechi E, Redenbaugh V, Morris PP, Carter JL, Wingerchuk DM, Tillema JM, Valencia-Sanchez C, Thakolwiboon S, Pittock SJ, Flanagan EP. Elsbernd P, et al. J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):14-18. doi: 10.1136/jnnp-2023-331137. J Neurol Neurosurg Psychiatry. 2023. PMID: 37221051 Free PMC article.
INTRODUCTION: Limited data exist on brain MRI enhancement in myelin-oligodendrocyte-glycoprotein (MOG) antibody-associated disease (MOGAD) and differences from aquaporin-4-IgG-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD), and multiple sclerosis (MS). …
INTRODUCTION: Limited data exist on brain MRI enhancement in myelin-oligodendrocyte-glycoprotein (MOG) antibody-associated disease (MOGAD) a …
Autoantibodies and pain.
Dawes JM, Vincent A. Dawes JM, et al. Curr Opin Support Palliat Care. 2016 Jun;10(2):137-42. doi: 10.1097/SPC.0000000000000211. Curr Opin Support Palliat Care. 2016. PMID: 27100817 Review.
For example, in complex regional pain syndrome, plasma exchange or intravenous immunoglobulins have been successful in reducing pain scores. Similarly, immunotherapies reduce autoantibody levels and pain in neuromyelitis optica and voltage-gated potassium cha …
For example, in complex regional pain syndrome, plasma exchange or intravenous immunoglobulins have been successful in reducing pain scor …
COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.
Sun D, Du Q, Wang R, Shi Z, Chen H, Zhou H. Sun D, et al. Front Immunol. 2023 Jul 27;14:1207514. doi: 10.3389/fimmu.2023.1207514. eCollection 2023. Front Immunol. 2023. PMID: 37575255 Free PMC article.
BACKGROUND: An increasing number of studies have elucidated a close nexus between COVID-19 phenotypes and neuromyelitis optica spectrum disorder (NMOSD), yet the causality between them remains enigmatic. ...RESULTS: The MR results demonstrated a nominal association …
BACKGROUND: An increasing number of studies have elucidated a close nexus between COVID-19 phenotypes and neuromyelitis optica …
1,371 results